|
Genentech: Commercializing a new technology
Amgen: Capitalizing on innovation
Human chromosomes and genetic trait inheritance
Poorly defined diseases discourage drug development
The Human Genome Project and drug development
Cytochrome p450 and pharmacogenomics
GMP: Building quality into products
Carnivorous fish as vegetarians
Blue jeans and biotechnology
Biofuel and bio-products: Back to the future
Using bacteria to make snow
Personalized medicine and drug sales
ESTs lack utility and enablement without proven use
Is it worth it for generics to challenge branded drugs?
Amgen v. Transkaryotic Therapies: Strategic patenting
Monsanto hit by $185 million torpedo
Johnson & Johnson sues Red Cross over trademark
The SNP Consortium
Erbitux: Poor study design
Vioxx: Anticipating and disclosing side effects
Fen-Phen: Risks of off-label use
AIDS and accelerated approval
Genzyme: Building an enterprise on orphans
The disproportionate returns of rare disease research
Biologic manufacturing: The significance of small changes
Starlink corn: Controlling biotechnology crops
State autonomy and federal laws
Directing innovation: The war on cancer
Presidential politics and biotechnology
Speedel: Spinning off to develop a shelved drug
Shareholder activism
Hybritech’s crucial role in San Diego’s biotechnology industry
Research Triangle Park
Chiron’s flu vaccine facility loses license
Venture capital: The poker analogy
Clinical trials provide valuation milestones
The cost of drug development
Repurposing thalidomide
Inhalable insulin: Holy grail or tiger trap?
Non-profit drug development
Cetus spreads itself too thin
Biotechnology myth: Build it and they will come
Risks of selling to “ideal” markets
Enbrel: Underestimating market demand
Avastin: Controlling off-label use
MedImmune v. Genentech: Licensees gain power
Cohen-Boyer: Broad licensing to maximize revenues
Licensing technology or keeping it in-house
Remicade: Resolving valuation disagreements
Exubera: When your partner doesn’t sell
Replacing founders
Flavr Savr tomatoes: Operating in unfamiliar markets
Preventing a product recall from bankrupting a company
Why did the biotechnology industry start, and prosper, in the United States?
Novartis cancels Indian investments over patent dispute
When research is done abroad
Merck’s Bermuda subsidiary runs afoul of U.S. tax laws
Want biotechnology funding? Use a shotgun!
| 
